SAN DIEGO--(BUSINESS WIRE)--Apricus Biosciences (“Apricus Bio,” formerly NexMed, Inc.) (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced results from a pre-clinical pharmacokinetic study showing the ability of NexACT to enable rectal delivery of biologics, such as human antibodies. Specifically, data from the study showed that rectal delivery of Rituxan®, formulated with NexACT, yielded similar blood levels of the antibody, as compared to delivery via subcutaneous route.
